A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety and Efficacy of a Single Treatment of AGN-214868 in Patients With Postherpetic Neuralgia.
Phase of Trial: Phase II
Latest Information Update: 03 Mar 2016
Price : $35 *
At a glance
- Drugs Senrebotase (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors Allergan
- 21 Oct 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
- 12 Mar 2015 Planned End Date changed from 1 Jun 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov.
- 12 Mar 2015 Planned primary completion date changed to 1 May 2015 as reported by ClinicalTrials.gov.